Skip to main content

Research Repository

Advanced Search

Outputs (10)

Aberrant fumarate metabolism links interferon release in diffuse systemic sclerosis. (2025)
Journal Article
Steadman, T., & O'Reilly, S. (2025). Aberrant fumarate metabolism links interferon release in diffuse systemic sclerosis. Journal of Dermatological Science, 117(2), 30-35. https://doi.org/10.1016/j.jdermsci.2025.01.002

Background
Systemic Sclerosis (SSc) is an idiopathic rheumatic inflammatory disease that is characterised by inflammation and skin fibrosis. Type I interferon is significantly elevated in the disease.
Objective
The objective of this study is to de... Read More about Aberrant fumarate metabolism links interferon release in diffuse systemic sclerosis..

The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis (2024)
Journal Article
Freedman, P., Schock, B., & O’Reilly, S. (2024). The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis. Cells, 13(14), Article 1205. https://doi.org/10.3390/cells13141205

Systemic sclerosis (SSc) is an autoimmune connective tissue disease with a triad of features that include vascular abnormalities, inflammation and skin and lung fibrosis. At the core of the disease is the activation of myofibroblasts from quiescent f... Read More about The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis.

Senescence and tissue fibrosis: opportunities for therapeutic targeting. (2024)
Journal Article
O'Reilly, S., Tsou, P.-S., & Varga, J. (online). Senescence and tissue fibrosis: opportunities for therapeutic targeting. Trends in Molecular Medicine, S1471-4914(24)00134-5. https://doi.org/10.1016/j.molmed.2024.05.012

Cellular senescence is a key hallmark of aging. It has now emerged as a key mediator in normal tissue turnover and is associated with a variety of age-related diseases, including organ-specific fibrosis and systemic sclerosis (SSc). This review discu... Read More about Senescence and tissue fibrosis: opportunities for therapeutic targeting..

Emerging therapeutic targets in systemic sclerosis. (2024)
Journal Article
O'Reilly, S. (2024). Emerging therapeutic targets in systemic sclerosis. Journal of Molecular Medicine, 102(4), 465-478. https://doi.org/10.1007/s00109-024-02424-w

Systemic sclerosis is an autoimmune connective tissue disease which is characterised by vascular perturbations, inflammation, and fibrosis. Although huge progress recently into the underlying molecular pathways that are perturbed in the disease, curr... Read More about Emerging therapeutic targets in systemic sclerosis..

S100A4 a classical DAMP as a therapeutic target in fibrosis. (2024)
Journal Article
O'Reilly, S. (2024). S100A4 a classical DAMP as a therapeutic target in fibrosis. Matrix Biology, 127, 1-7. https://doi.org/10.1016/j.matbio.2024.01.002

Fibrosis regardless of aetiology is characterised by persistently activated myofibroblasts that are contractile and secrete excessive amounts of extracellular matrix molecules that leads to loss of organ function. Damage-Associated Molecular Patterns... Read More about S100A4 a classical DAMP as a therapeutic target in fibrosis..

The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itaconate, 4-Octyl Itaconate, Is Anti-Fibrotic in Systemic Sclerosis (2021)
Journal Article
Henderson, J., Dayalan Naidu, S., Dinkova-Kostova, A. T., Przyborski, S., Stratton, R., & O′Reilly, S. (2021). The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itaconate, 4-Octyl Itaconate, Is Anti-Fibrotic in Systemic Sclerosis. Cells, 10(8), https://doi.org/10.3390/cells10082053

Systemic sclerosis (SSc) is an autoimmune connective tissue disease that leads to skin fibrosis. Altered metabolism has recently been described in autoimmune diseases and SSc. Itaconate is a product of the Krebs cycle intermediate cis-aconitate and i... Read More about The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itaconate, 4-Octyl Itaconate, Is Anti-Fibrotic in Systemic Sclerosis.

Circulating Gremlin-1 is elevated in systemic sclerosis patients (2021)
Journal Article
O’Reilly, S. (2021). Circulating Gremlin-1 is elevated in systemic sclerosis patients. Journal of Scleroderma and Related Disorders, 6(3), 286-289. https://doi.org/10.1177/23971983211036571

Introduction: Systemic sclerosis is an autoimmune connective tissue disease in which there is activation of the immune system, vascular disease and fibrosis. Activation of quiescent fibroblasts to myofibroblasts is key to disease pathogenesis. Gremli... Read More about Circulating Gremlin-1 is elevated in systemic sclerosis patients.

Wnt antagonist DKK‐1 levels in systemic sclerosis are lower in skin but not blood and is regulated by microRNA33a‐3p (2020)
Journal Article
Henderson, J., Pryzborski, S., Stratton, R., & O’Reilly, S. (2020). Wnt antagonist DKK‐1 levels in systemic sclerosis are lower in skin but not blood and is regulated by microRNA33a‐3p. Experimental Dermatology, 30(1), 162-168. https://doi.org/10.1111/exd.14136

Background: Systemic sclerosis is an autoimmune skin disease which is associated with inflammation and resulting skin fibrosis. Myofibroblasts are the key cell type associated with the fibrosis but how they are differentiated is not clear. DKK‐1 is a... Read More about Wnt antagonist DKK‐1 levels in systemic sclerosis are lower in skin but not blood and is regulated by microRNA33a‐3p.